Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, will showcase its highly multiplexed cellular profiling solutions for immunology and immunotherapy research as a Gold Sponsor at the 34th Congress of the International Society for Advancement of Cytometry (CYTO® 2019) in Vancouver, British Columbia.
“The progress being made to advance our understanding of health and disease using CyTOF® technology has been truly impressive. Now used in more than 40 clinical research trials and by multiple consortia around the world, CyTOF technology is offering new insights in cancer, autoimmune and infectious disease, neurological disorders and more,” said Chris Linthwaite, President and CEO of Fluidigm. “Over the next few days we’ll be sharing our latest highly multiplexed applications to deliver new insights into the immunome, accelerate biomarker discovery and power the development of new immunotherapies.”
Featured Immunology and Immunotherapy Research Applications
CYTO 2019 Tutorial
On Sunday, June 23, Fluidigm will host a tutorial titled Deep Profiling of Immune Cell Phenotypes and Function from Circulation to Tissue with CyTOF Technology. At the event Michelle Poulin, PhD, of Fluidigm will introduce the Maxpar Direct Immune Profiling System. Data demonstrating high repeatability, site-to-site reproducibility and software precision will be shown. Thomas Ashhurst, BSc, High-Dimensional Cytometry Specialist at the Sydney Cytometry Facility in Australia, will present his research on how viral infection of the central nervous system stimulates a rapid influx of bone marrow-derived monocytes and macrophages into the parenchyma. He will describe use of Imaging Mass Cytometry to perform high-dimensional tissue profiling to gain a more comprehensive analysis of the key factors involved in this mobilization of the immune system.
During the meeting, researchers from leading cancer centers and academic medical centers will share more than 70 presentations and posters using Fluidigm technologies. Of these, a few notable presentations include:
More information on the Fluidigm events, products and research presentations and posters at CYTO 2019 using Fluidigm technologies can be found at Fluidigm Booth 426 or at fluidigm.com/events/cyto-2019.
8th Annual Fluidigm Mass Cytometry Summit
In advance of CYTO 2019, Fluidigm will kick off its annual Mass Cytometry Summit today in Vancouver. The largest global mass cytometry meeting of its kind, the action-packed two-day program includes more than 30 speakers from around the world. New this year are two special-topic breakout sessions: a panel discussion for core directors, and presentations and discussion on best practices from experts. This year’s Summit will include opening remarks from Andrew Quong, who became Fluidigm’s Chief Science Officer in May of this year. He is the first to serve in this type of role at Fluidigm since 2012. Marc Unger served as Chief Scientific Officer from 2007 to 2012. For more information visit fluidigm.com/summit2019.
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Helios, Hyperion, Imaging Mass Cytometry, Immune Profiling Assay, Maxpar and Pathsetter are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of immune profiling and Fluidigm products for mass cytometry and Imaging Mass Cytometry. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423